• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share - Product Image

Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

  • Published: January 2013
  • 60 Pages
  • GBI Research

FEATURED COMPANIES

  • Merck & Co Inc
  • Novartis AG (Novartis)
  • Pfizer Inc.
  • MORE

This report provides insights into the global statins market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia. The report gives insights into the share of generics in the global statins market for the years 2011 and 2018.

The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan.

The report also includes insights into the statins R&D product pipeline, and explores the competitive landscape, including major players in the statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and co-development deals that have taken place in the statins market.

Statins have READ MORE >

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Statins Market to 2018 - Introduction
3 Statins Market to 2018 - Global Statins Market
3.1 Introduction
3.2 Global Market Forecast
3.2.1 Branded and Generic Market Share
3.3 Annual Cost of Treatment
3.4 Treatment Usage Patterns
3.4.1 Disease Population
3.4.2 Treatment Seeking Population
3.4.3 Diagnosed Population
3.4.4 Prescription Population
3.5 Drivers and Restraints to the Statins Market
3.5.1 Drivers to the Statins Market
3.5.2 Restraints to the Statins Market
3.6 Major Marketed Products
3.6.1 Crestor (rosuvastatin calcium)
3.6.2 Lipitor (atorvastatin calcium)
3.6.3 Vytorin (ezetimibe/simvastatin)
3.6.4 Zocor (simvastatin)
3.6.5 Livalo (pitavastatin calcium)
3.6.6 Lescol XL (fluvastatin sodium)
3.6.7 Pravachol (pravastatin sodium)
4 Statins Market to 2018 - Statins Market in the US
4.1 Market
4.2 Annual Cost of Therapy (ACT)
4.3 Treatment Usage Pattern
4.3.1 Diseased Population
4.3.2 Treatment Seeking Population
4.3.3 Diagnosed Population
4.3.4 Patients on Statins Therapy
5 Statins Market to 2018 - Statins Market in the Top Five Countries of Europe
5.1 Market
5.2 Annual Cost of Therapy
5.3 Treatment Usage Pattern
5.3.1 Diseased Population
5.3.2 Treatment Seeking Population
5.3.3 Diagnosed Population
5.3.4 Patients on Statins Therapy
6 Statins Market to 2018 - Statins Market in Japan
6.1 Market
6.2 Annual Cost of Therapy
6.3 Treatment Usage Pattern
6.3.1 Diseased Population
6.3.2 Treatment Seeking Population
6.3.3 Diagnosed Population
6.3.4 Patients on Statins Therapy
7 Statins Market to 2018 - Product Pipeline Anlaysis
7.1 Introduction
7.2 Pipeline Analysis
8 Statins Market to 2018 - Competitive Landscape
8.1 Pfizer Inc.
8.1.1 Company Overview
8.1.2 SWOT Analysis
8.2 AstraZeneca PLC (AstraZeneca)
8.2.1 Company Overview
8.2.2 SWOT Analysis
8.3 Merck & Co Inc
8.3.1 Company Overview
8.3.2 SWOT Analysis
8.4 Novartis AG (Novartis)
8.4.1 Company Overview
8.4.2 SWOT Analysis
9 Statins Market to 2018 - Strategic Consolidation
9.1 Merger and Acquisition (M&A) Deals
9.2 Licensing Deals
9.2.1 Licensing Deals by Geography
9.3 Co-development Deals
10 Statins Market to 2018 - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Primary Research
10.4.4 Therapeutic Landscape
10.4.5 Geographical Landscape
10.4.6 Pipeline Analysis
10.4.7 Competitive Landscape
10.5 Expert Panel Validation
10.6 Contact Us
10.7 Disclaimer

1.1 List of Tables
Table 1: Statins Market, Global, Revenue ($bn), 2004-2011
Table 2: Statins Market, Global, Revenue Forecast ($bn), 2011 -2018
Table 3: Statins Market, Global, ACT ($), 2004-2011
Table 4: Statins Market, Global, ACT ($), 2011-2018
Table 5: Statins Market, Global, Treatment Usage Patterns (million), 2004-2011
Table 6: Statins Market, Global, Treatment Usage Patterns (million), 2011-2018
Table 7: Statins Market, the US, Revenue ($bn), 2004-2011
Table 8: Statins Market, the US, Revenue Forecast ($bn), 2011-2018
Table 9: Statins Market, the US, ACT ($), 2004-2011
Table 10: Statins Market, the US, ACT ($), 2011-2018
Table 11: Statins Market, the US, Treatment Usage Pattern (million), 2004-2011
Table 12: Statins Market, the US, Treatment Usage Pattern (million), 2011-2018
Table 13: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011
Table 14: Statins Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018
Table 15: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2011
Table 16: Statins Market, Top Five Countries of Europe, ACT ($), 2011-2018
Table 17: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2011
Table 18: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011-2018
Table 19: Statins Market, Japan, Revenue ($bn), 2004-2011
Table 20: Statins Market, Japan, Revenue Forecast ($bn), 2011-2018
Table 21: Statins Market, Japan, ACT ($), 2004-2011
Table 22: Statins Market, Japan, ACT ($), 2011-2018
Table 23: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2011
Table 24: Statins Market, Japan, Treatment Usage Pattern (million), 2011-2018
Table 25: Statins Market, Global, Product Pipeline, 2012
Table 26: Statins Market, M&A Deals ($m), 2008-2011
Table 27: Statins Market, Licensing Deals, 2005-2011
Table 28: Statins Market, Co-Development Deals, 2005-2008

1.2 List of Figures
Figure 1: Statins Market, Global, Revenue ($bn), 2004-2018
Figure 2: Statins Market, Global, Generic and Branded Market Share (%), 2011 and 2018
Figure 3: Statins Market, Global, ACT ($), 2004-2018
Figure 4: Statins Market, Global, Treatment Usage Patterns (million), 2004-2018
Figure 5: Statins Market, Global, Drivers and Barriers, 2011
Figure 6: Statins Market, the US, Revenue ($bn), 2004 -2018
Figure 7: Statins Market, the US, ACT ($), 2004-2018
Figure 8: Statins Market, the US, Treatment Usage Pattern (million), 2004-2018
Figure 9: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2018
Figure 10: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2018
Figure 11: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2018
Figure 12: Statins Market, Japan, Revenue ($bn), 2004-2018
Figure 13: Statins Market, Japan, ACT ($), 2004-2018
Figure 14: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2018
Figure 15: Statins Market, Global, Top Companies' Market Share (%), 2011
Figure 16: Statins Market, Pfizer Inc., SWOT Analysis, 2011
Figure 17: Statins Market, AstraZeneca, SWOT Analysis, 2011
Figure 18: Statins Market, Merck & Co. Inc., SWOT Analysis, 2011
Figure 19: Statins Market, Novartis, SWOT Analysis, 2011
Figure 20: Statins Market, Strategic Consolidation, 2005-2011
Figure 21: GBI Research Market Forecasting Model

- Pfizer Inc.

- AstraZeneca PLC (AstraZeneca)

- Merck & Co Inc

- Novartis AG (Novartis)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos